Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN studySilvia Nozza, Adriano Lazzarin, Andrea Antinori et al.|Clinical Microbiology and Infection|2014Cited by 26